Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KROS Keros Therapeutics	$13.75 -4.2%	$13.99	$9.12 ▼ $72.37	$558.53M	1.26	864,643 shs	458,330 shs
MNMD Mind Medicine (MindMed)	$8.88	$7.25	$4.70 ▼ $10.44	$670.88M	2.45	1.33 million shs	1.25 million shs
MOLN Molecular Partners	$3.63 -0.7%	$3.78	$3.36 ▼ $12.22	$146.38M	1.1	14,433 shs	408 shs
SAGE Sage Therapeutics	$9.11 -0.3%	$7.88	$4.62 ▼ $13.47	$570.47M	0.29	1.34 million shs	1.93 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KROS Keros Therapeutics	-0.90%	-0.76%	+6.69%	+2.06%	-71.12%
MNMD Mind Medicine (MindMed)	+3.50%	+9.63%	+32.34%	+53.90%	+5.84%
MOLN Molecular Partners	+1.11%	+0.94%	-3.23%	-7.83%	-43.88%
SAGE Sage Therapeutics	+0.11%	-0.76%	+0.22%	+23.01%	-24.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KROS Keros Therapeutics	2.0994 of 5 stars	3.3	1.0	0.0	2.7	3.3	0.0
MNMD Mind Medicine (MindMed)	2.1221 of 5 stars	3.6	1.0	0.0	2.9	0.8	0.6
MOLN Molecular Partners	3.1203 of 5 stars	3.8	5.0	0.0	2.7	0.0	0.6
SAGE Sage Therapeutics	3.3381 of 5 stars	2.0	4.0	4.1	1.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KROS Keros Therapeutics	2.50	Moderate Buy	$30.56	122.22% Upside
MNMD Mind Medicine (MindMed)	3.27	Buy	$25.50	187.16% Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	231.03% Upside
SAGE Sage Therapeutics	1.94	Reduce	$8.75	-3.99% Downside

Current Analyst Ratings Breakdown

Latest MOLN, SAGE, KROS, and MNMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00
5/30/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	KROS Keros Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$41.00 ➝ $26.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KROS Keros Therapeutics	$3.55M	157.33	N/A	N/A	$14.11 per share	0.97
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$3.21 per share	N/A
MOLN Molecular Partners	$5.65M	25.91	N/A	N/A	$3.99 per share	0.91
SAGE Sage Therapeutics	$41.24M	13.83	N/A	N/A	$7.60 per share	1.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KROS Keros Therapeutics	-$187.35M	-$0.18	N/A	N/A	N/A	1.96%	0.75%	0.69%	8/6/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.29	N/A	N/A	N/A	N/A	-40.33%	-32.13%	8/12/2025 (Estimated)
MOLN Molecular Partners	-$61.39M	-$1.92	N/A	N/A	N/A	N/A	-42.20%	-38.12%	8/25/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)

Latest MOLN, SAGE, KROS, and MNMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MNMD Mind Medicine (MindMed)	-$0.37	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	KROS Keros Therapeutics	-$1.13	N/A	N/A	N/A	$3.83 million	N/A
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	N/A	N/A	N/A	$16.69 million	N/A
5/15/2025	Q1 2025	MOLN Molecular Partners	-$0.3855	-$0.50	-$0.1145	-$0.50	N/A	N/A
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A
5/6/2025	Q1 2025	KROS Keros Therapeutics	-$0.01	$3.62	+$3.63	$3.62	$84.62 million	$211.25 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KROS Keros Therapeutics	N/A	19.29	19.29
MNMD Mind Medicine (MindMed)	0.10	7.27	7.27
MOLN Molecular Partners	N/A	15.28	15.28
SAGE Sage Therapeutics	N/A	9.13	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KROS Keros Therapeutics	71.56%
MNMD Mind Medicine (MindMed)	27.91%
MOLN Molecular Partners	26.55%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
KROS Keros Therapeutics	20.60%
MNMD Mind Medicine (MindMed)	2.45%
MOLN Molecular Partners	5.93%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KROS Keros Therapeutics	100	40.62 million	32.25 million	Optionable
MNMD Mind Medicine (MindMed)	40	75.55 million	73.70 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

MOLN, SAGE, KROS, and MNMD Headlines

Recent News About These Companies

Sage Therapeutics (NASDAQ:SAGE) Shares Pass Above Fifty Day Moving Average - Should You Sell?

July 16 at 5:36 AM | marketbeat.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

July 14, 2025 | businesswire.com

Sage Therapeutics (NASDAQ:SAGE) Stock Rating Lowered by Scotiabank

July 11, 2025 | americanbankingnews.com

Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock

July 9, 2025 | nasdaq.com

Scotiabank Downgrades Sage Therapeutics (SAGE)

July 9, 2025 | msn.com

Scotiabank Reiterates "Sector Perform" Rating for Sage Therapeutics (NASDAQ:SAGE)

July 8, 2025 | marketbeat.com

Wealth Enhancement Advisory Services LLC Takes $347,000 Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 8, 2025 | marketbeat.com

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from Analysts

July 6, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Share Price Passes Above Two Hundred Day Moving Average - Here's Why

July 4, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Shares Pass Above 50 Day Moving Average - Here's Why

July 4, 2025 | marketbeat.com

Rx Rundown: AbbVie, Healthline, Beckley Psytech and more

July 3, 2025 | mmm-online.comM

Sage’s Search for Lifeline Ran Into Defiant Biogen CEO

July 3, 2025 | biospace.comB

M&A ramped up in June, with blueBird, Sage and Snyk tie-ups

July 2, 2025 | bizjournals.com

Boston-area pharma company to lay off entire 300-person staff after sale

July 1, 2025 | msn.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)

July 1, 2025 | globenewswire.com

What Makes Sage Therapeutics (SAGE) a New Buy Stock

July 1, 2025 | zacks.com

Sage Therapeutics cuts most of its workforce following acquisition

July 1, 2025 | statnews.comS

Sage lays off entire staff of 338 amid takeover by Supernus

July 1, 2025 | fiercepharma.comF

This common kitchen herb ingredient could help target or slow Alzheimer’s

June 29, 2025 | msn.com

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

June 23, 2025 | msn.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, SAGE, KROS, and MNMD Company Descriptions

Keros Therapeutics NASDAQ:KROS

$13.75 -0.61 (-4.25%)

Closing price 04:00 PM Eastern

Extended Trading

$14.01 +0.26 (+1.89%)

As of 04:30 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Mind Medicine (MindMed) NASDAQ:MNMD

$8.88 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$8.88 -0.01 (-0.06%)

As of 04:30 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Molecular Partners NASDAQ:MOLN

$3.62 -0.03 (-0.68%)

Closing price 03:27 PM Eastern

Extended Trading

$3.62 0.00 (0.00%)

As of 04:04 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Sage Therapeutics NASDAQ:SAGE

$9.11 -0.03 (-0.33%)

Closing price 04:00 PM Eastern

Extended Trading

$9.11 +0.00 (+0.01%)

As of 04:20 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time